Skip to content Skip to footer
Subscribe Now
EVENTS
HLTH USA 2025 | Oct 19-22 | Las Vegas, NV 
EVERYONE has a heroic story to tell, their own legend to fulfill and HLTH is forging ahead into new realms of possibilities, gathering 12,000+ influential leaders, executives and visionaries who are passionately creating the next generation of healthcare. At HLTH you can foster meaningful connections, gain insights on cutting-edge trends, enhance your professional journey, or…
August 12, 20250Comments
SPOTLIGHT
CXO Talks: Thomas Chalberg & Annahita Keravala from Genascence in a Candid Conversation with PharmaShots
Shots: PharmaShots speaks with Thomas Chalberg, Founder and CEO of Genascence Corporation, and Annahita Keravala, Founder and CSO of Genascence Corporation Thomas and Annahita speak eloquently about Genascence's current lead program, GNSC-001, for osteoarthritis of the knee, and shed light on the unmet medical needs in the disease The duo highlighted the safety and tolerability…
August 11, 20250Comments
VIEWPOINTS
Jazz Pharmaceuticals at ASCO 2025: Robert Iannone in a Stimulating Conversation with PharmaShots
Shots:   Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025   Robert Iannone, CMO, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared four-year follow-up data from an ongoing P-II trial of Ziihera in combination with CT for…
August 11, 20250Comments
NEWS
Arvinas Reports the US FDA’s NDA Acceptance of Vepdegestrant for ESR1-Mutated Breast Cancer
Shots: The US FDA has accepted NDA of vepdegestrant to treat pts with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy (PDUFA: Jun 5, 2026) NDA was backed by P-III (VERITAC-2) trial assessing vepdegestrant alone vs fulvestrant in mentioned pts (n=624) previously treated with CDK4/6 inhibitor + endocrine therapy Trial showed…
August 11, 20250Comments
NEWS
CSL Receives Health Canada’s Approval for Andembry as a Prophylactic Treatment of Hereditary Angioedema (HAE)
Shots:  Health Canada has approved Andembry (garadacimab) for HAE pts (≥12yrs) Approval was based on P-III (VANGUARD) trial assessing Andembry (n=39) vs PBO (n=25) for 6mos., which showed 62% pts remained attack-free, with reduction in overall HAE attacks by >99% median & 89.2% mean; data was published in The Lancet Interim analysis of the ongoing OLE…
August 11, 20250Comments
NEWS
GSK Reports the US FDA’s sNDA Acceptance and Priority Review of Blujepa for Uncomplicated Urogenital Gonorrhoea
Shots: The US FDA has accepted sNDA & granted priority review to Blujepa (gepotidacin) for the treatment of pts (≥12yrs.; ≥45kg) with uncomplicated urogenital gonorrhoea (PDUFA: Dec 11, 2025); regulatory review is ongoing in the UK & Australia sNDA was backed by P-III (EAGLE-1) trial assessing Blujepa (2 doses × 3000mg; PO) vs ceftriaxone (500mg; IM)…
August 11, 20250Comments